According to IMS, Fresenius Kabi’s market share for Propofol and its equivalent, Diprivan, was 75% in December 2014 (November: 73%). Since March 2014, IMS data on our competition has included direct sales to hospitals. Fresenius Kabi does not report direct sales; our market share is therefore not fully reflected in IMS data.

Argatroban injection expands Kabi's anticoagulant product portfolio. Now available as a 250mg/2.5mL presentation in a single dose vial.

FDA has extended regulatory discretion on sodium chloride infusion solutions (until May 31) and trace elements (until June 30,) but has discontinued discretion to import Glycophos (Dec. 31, 2014). Accordingly, Fresenius Kabi expects lower 2015 sales from products imported under regulatory discretion. Fresenius Kabi expects 2015 IV generic product launches to be backloaded.

Moxifloxacin injection further expands the Fresenius Kabi anti-infective portfolio. It is available in the company's proprietary Freeflex® bag.

Cisatracurium Besylate Injection, a neuromuscular blocker, further expands Fresenius Kabi's anesthesia portfolio. Now available in three presentations.

Glucagon injection expands Fresenius Kabi's U.S. critical care portfolio and is sold in 10-packs of 1mg vials.